As we embark on the future, scientists are tasked with offering improved opportunities for patient health and quality of life through innovation. This paper attempts to review cannabidiol (CBD) history, current uses, and future directions based on innovative technology, specifically intravenous administration of CBD and its relevant potential to improve health and decrease inflammation. Dr. Nathan Goodyear, M.D., a renowned Oncology specialist, shares his insights as a part of his journey utilizing CBD to support patient care.
CBD is one of the many phytocannabinoids. It is a natural compound dating back 11,700 years, has been used in various forms since its discovery in 1940. Historically, cannabidiol has been primarily administered through oral routes, such as tinctures, capsules, or sublingual lozenges. However, the bioavailability of oral CBD is low, requiring higher and more frequent dosing for therapeutic effect. Intravenous administration of CBD is an optimal delivery method which theoretically offers improved bioavailability and enhances symptom relief for patients. There is limited research available on intravenous administration of CBD. However, preliminary research being conducted by PICO-IV suggests a prolonged metabolic half-life. Historical research suggests that the half-life for intravenous and inhalation delivery being 24+/- 6 hours and 31+/-4 hours, respectively; however, more research is necessary as there is a possibility that the half-life may be significantly longer. Cannabidiol has been known to cause numerous significant effects, including analgesic, anti-nausea, anti-emetic, anxiolytic, anti-insomnia, anti-depressant, anti-psychotic, anti-convulsant, anti-asthmatic, immunomodulatory, antioxidant, anti-inflammatory, anti-bacterial, neuroprotective, improves BBB integrity/permeability, and anti-cancer which suggests significant efficacy in the utilization of CBD via a possible new “gold standard” intravenous administration route.
Download & Read the Complete White Paper here:
Or continue reading here on Pico IV:
Comentarios